Hydroquinone-associated ochronosis is "rare" in U.S., NDMA's Soller tells FDA.
This article was originally published in The Rose Sheet
Executive Summary
HYDROQUINONE-ASSOCIATED OCHRONOSIS IS "RARE" IN U.S., Nonprescription Drug Manufacturers Association Senior VP and Director of Science & Technology William Soller, PhD, said at a July 10 OTC "feedback" meeting on the skin bleaching ingredient. Soller's presentation responded to an FDA request for additional information on exogenous ochronosis, a condition causing a deep bluish or gray discoloration of the skin usually on the face, and its possible link to exposure to certain chemicals including hydroquinone.